Home » Stocks » OMER

Omeros Corporation (OMER)

Stock Price: $14.19 USD -0.05 (-0.35%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 884.44M
Revenue (ttm) 71.34M
Net Income (ttm) -144.12M
Shares Out 61.93M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $14.19
Previous Close $14.24
Change ($) -0.05
Change (%) -0.35%
Day's Open 14.36
Day's Range 13.95 - 14.38
Day's Volume 216,607
52-Week Range 9.25 - 23.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-assoc...

1 month ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell tra...

1 month ago - Business Wire

Omeros (OMER) announces initial results from a phase I study of OMS906.

1 month ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

1 month ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual C...

1 month ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are ad...

1 month ago - Newsfile Corp

NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised to conta...

1 month ago - PRNewsWire

Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.

1 month ago - Zacks Investment Research

New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are ad...

1 month ago - Newsfile Corp

Omeros Corporation (NASDAQ: OMER) has announced preliminary results from the second cohort (n=10) of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. The patients were part o...

1 month ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

1 month ago - Business Wire

The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.

2 months ago - Zacks Investment Research

Omeros Corporation (NASDAQ: OMER) has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell transplant-associated thrombotic microangiopathy...

2 months ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

2 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros' pivotal trial of narsoplimab for the treatment of hematopoietic stem cell...

2 months ago - Business Wire

Omeros (OMER) delivered earnings and revenue surprises of 1.96% and -5.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Omeros (NASDAQ:OMER) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 7.55% over the past year to ($0.57), which were in ...

2 months ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

2 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021,...

2 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) di...

2 months ago - Business Wire

SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began...

4 months ago - Business Wire

Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 3.45% over the past year to ($0.60), which beat the esti...

4 months ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

4 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Mond...

4 months ago - Business Wire

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial...

5 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associate...

6 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare ...

6 months ago - Business Wire

Omeros: A Ripening Fruit Ready To Pick

7 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Om...

7 months ago - Business Wire

Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FD...

8 months ago - Business Wire

Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Omeros (OMER) delivered earnings and revenue surprises of 33.33% and 39.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

8 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9...

8 months ago - Business Wire

Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual e...

8 months ago - Business Wire

The Omeros narsoplimab ship is finally coming in after long voyages in treacherous waters. Omeros' liquidity is improved but will likely remain challenging.

8 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy ...

9 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company's lead human monoc...

9 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated t...

9 months ago - Business Wire

OMER share price has been depressed over continued uncertainty regarding sales of their primary revenue-driver.

9 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular soluti...

9 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D.

10 months ago - Business Wire

Omeros (OMER) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. T...

10 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administr...

10 months ago - Business Wire

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HS... [Read more...]

Industry
Biotechnology
IPO Date
Oct 8, 2009
CEO
Gregory Demopulos
Employees
277
Stock Exchange
NASDAQ
Ticker Symbol
OMER
Full Company Profile

Financial Performance

In 2020, Omeros's revenue was $73.81 million, a decrease of -33.98% compared to the previous year's $111.81 million. Losses were -$138.06 million, 63.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Omeros stock is "Buy." The 12-month stock price forecast is 37.43, which is an increase of 163.78% from the latest price.

Price Target
$37.43
(163.78% upside)
Analyst Consensus: Buy